Quantitative analysis of diffusion weighted imaging in rectal cancer during radiotherapy using a magnetic resonance imaging integrated linear accelerator.
Apparent diffusion coefficient
Diffusion weighted imaging
MR-Linac
MRI
Rectal cancer
Journal
Physics and imaging in radiation oncology
ISSN: 2405-6316
Titre abrégé: Phys Imaging Radiat Oncol
Pays: Netherlands
ID NLM: 101704276
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
29
09
2021
revised:
16
05
2022
accepted:
02
06
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
Magnetic resonance imaging integrated linear accelerator (MR-Linac) platforms enable acquisition of diffusion weighted imaging (DWI) during treatment providing potential information about treatment response. Obtaining DWI on these platforms is technically different from diagnostic magnetic resonance imaging (MRI) scanners. The aim of this project was to determine feasibility of obtaining DWI and calculating apparent diffusion coefficient (ADC) parameters longitudinally in rectal cancer patients on the MR-Linac. Nine patients undergoing treatment on MR-Linac had DWI acquired using b-values 0, 30, 150, 500 s/mm Seven out of nine patients were included in the analysis; all demonstrated downstaging at follow-up. A total of 63 out of 70 DWI were analysed (7 excluded due to poor image quality). An increasing trend of ADC median for GTV (1.15 × 10 DWI assessment in rectal cancer patients on MR-Linac is feasible. Initial results provide foundations for further studies to determine DWI use for treatment adaptation in rectal cancer.
Sections du résumé
Background and purpose
UNASSIGNED
Magnetic resonance imaging integrated linear accelerator (MR-Linac) platforms enable acquisition of diffusion weighted imaging (DWI) during treatment providing potential information about treatment response. Obtaining DWI on these platforms is technically different from diagnostic magnetic resonance imaging (MRI) scanners. The aim of this project was to determine feasibility of obtaining DWI and calculating apparent diffusion coefficient (ADC) parameters longitudinally in rectal cancer patients on the MR-Linac.
Materials and methods
UNASSIGNED
Nine patients undergoing treatment on MR-Linac had DWI acquired using b-values 0, 30, 150, 500 s/mm
Results
UNASSIGNED
Seven out of nine patients were included in the analysis; all demonstrated downstaging at follow-up. A total of 63 out of 70 DWI were analysed (7 excluded due to poor image quality). An increasing trend of ADC median for GTV (1.15 × 10
Conclusions
UNASSIGNED
DWI assessment in rectal cancer patients on MR-Linac is feasible. Initial results provide foundations for further studies to determine DWI use for treatment adaptation in rectal cancer.
Identifiants
pubmed: 35756883
doi: 10.1016/j.phro.2022.06.003
pii: S2405-6316(22)00051-3
pmc: PMC9214864
doi:
Types de publication
Journal Article
Langues
eng
Pagination
32-37Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: SL reports travel and educational grants from Elekta (Elekta AB, Stockholm, Sweden). SH reports non-financial support from Elekta (Elekta AB, Stockholm, Sweden), non-financial support from Merck Sharp & Dohme (MSD), personal fees and non-financial support from Roche outside the submitted work. SB reports travel and educational grants from Elekta (Elekta AB, Stockholm, Sweden)..
Références
Ann Surg Oncol. 2012 Sep;19(9):2822-32
pubmed: 22434243
AJR Am J Roentgenol. 2007 Jun;188(6):1622-35
pubmed: 17515386
Clin Transl Radiat Oncol. 2019 Apr 08;18:66-67
pubmed: 31341978
Ann Surg. 2016 Mar;263(3):458-64
pubmed: 24263329
Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):883-8
pubmed: 10705009
J Magn Reson Imaging. 2014 Jul;40(1):146-50
pubmed: 24127172
Clin Oncol (R Coll Radiol). 2016 Feb;28(2):152-160
pubmed: 26625960
Eur J Radiol. 2021 Mar;136:109504
pubmed: 33421885
Magn Reson Imaging. 2015 Jun;33(5):516-24
pubmed: 25660642
Br J Radiol. 2017 Mar;90(1071):20160739
pubmed: 28079398
Clin Transl Radiat Oncol. 2019 Apr 02;18:54-59
pubmed: 31341976
PLoS Biol. 2015 Jul 23;13(7):e1002203
pubmed: 26204162
Comput Biol Med. 2016 Feb 1;69:203-12
pubmed: 26773941
Front Oncol. 2020 May 08;10:704
pubmed: 32457842
Strahlenther Onkol. 2013 Feb;189(2):117-22
pubmed: 23283590
Radiother Oncol. 2021 Jan;154:172-178
pubmed: 32976875
Eur Radiol. 2011 May;21(5):987-95
pubmed: 20978768
PLoS One. 2016 Apr 21;11(4):e0153944
pubmed: 27100991
Radiother Oncol. 2019 Apr;133:156-162
pubmed: 30935572
Radiat Oncol. 2021 Jan 19;16(1):16
pubmed: 33468176
Radiology. 2017 Feb;282(2):418-428
pubmed: 27253423
Radiother Oncol. 2014 Oct;113(1):1-9
pubmed: 25281582
Ann Surg. 2004 Oct;240(4):711-7; discussion 717-8
pubmed: 15383798
Lancet Oncol. 2010 Sep;11(9):835-44
pubmed: 20692872
Oncotarget. 2017 Apr 27;8(43):75597-75606
pubmed: 29088894
Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):752-60
pubmed: 15936556
Radiother Oncol. 2020 Dec;153:106-113
pubmed: 33017604
Radiology. 2010 Jan;254(1):170-8
pubmed: 20019139
Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):907-16
pubmed: 16751073
Br J Radiol. 2017 Apr;90(1072):20151078
pubmed: 28055248
Curr Colorectal Cancer Rep. 2018;14(2):37-55
pubmed: 29576755
Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):843-56
pubmed: 11020583
Lancet Oncol. 2007 Jul;8(7):625-33
pubmed: 17613424
Phys Med Biol. 2009 Jun 21;54(12):N229-37
pubmed: 19451689
Lancet Oncol. 2011 Jun;12(6):575-82
pubmed: 21596621
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):74-80
pubmed: 22763027
Medicine (Baltimore). 2015 Feb;94(6):e517
pubmed: 25674749
Gastrointest Cancer Res. 2013 Sep;6(5-6):137-43
pubmed: 24312687
Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40
pubmed: 28881920
J Magn Reson Imaging. 2017 Jul;46(1):175-183
pubmed: 27981667
Cancer. 1994 Jun 1;73(11):2680-6
pubmed: 8194005
Acta Oncol. 2016 Dec;55(12):1392-1399
pubmed: 27762654